Literature DB >> 3316029

Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic.

R Curtiss1, S M Kelly.   

Abstract

Salmonella typhimurium SR-11 mutants with cya::Tn10 or crp::Tn10 mutations were found to be avirulent and immunogenic for BALB/c mice. Fusaric acid-resistant derivatives with deletions of the Tn10 and adjacent DNA sequences were constructed in S. typhimurium SR-11 strains with or without the virulence plasmid pStSR100. These delta cya delta crp strains grew more slowly than wild-type strains. They possessed wild-type ability to attach to, invade, and persist in gut-associated lymphoid tissue for up to a week but exhibited a diminished ability to reach mesenteric lymph nodes and the spleen. Mice 4 to 8 weeks old were resistant to oral infection with 10(9) cells of several different delta cya and delta cya delta crp strains (the equivalent to 10(4) 50% lethal doses of wild-type S. typhimurium SR-11) and 30 days after immunization became resistant to oral challenge with 10(3) to 10(4) 50% lethal doses of wild-type S. typhimurium SR-11.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316029      PMCID: PMC260025          DOI: 10.1128/iai.55.12.3035-3043.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  Hybridization between Escherichia coli and Shigella.

Authors:  S E LURIA; J W BURROUS
Journal:  J Bacteriol       Date:  1957-10       Impact factor: 3.490

2.  Phage P22-mutants with increased or decreased transduction abilities.

Authors:  H Schmieger
Journal:  Mol Gen Genet       Date:  1972

3.  Salmonella typhimurium mutants affecting establishment of lysogeny.

Authors:  R N Rao; C V Raj
Journal:  Mol Gen Genet       Date:  1973-09-05

4.  Pleiotropic deficiency of carbohydrate utilization in an adenyl cyclase deficient mutant of Escherichia coli.

Authors:  R L Perlman; I Pastan
Journal:  Biochem Biophys Res Commun       Date:  1969-09-24       Impact factor: 3.575

5.  Parental functions during conjugation in Escherichia coli K-12.

Authors:  R Curtiss; L J Charamella; D R Stallions; J A Mays
Journal:  Bacteriol Rev       Date:  1968-12

6.  Fimbriation, pellicle formation and the amount of growth of salmonellas in broth.

Authors:  D C Old; I Corneil; L F Gibson; A D Thomson; J P Duguid
Journal:  J Gen Microbiol       Date:  1968-04

7.  Immunity in experimental salmonellosis. II. Basis for the avirulence and protective capacity of gal E mutants of Salmonella typhimurium.

Authors:  R Germanier; E Fürer
Journal:  Infect Immun       Date:  1971-12       Impact factor: 3.441

8.  Requirement of adenosine 3', 5'-cyclic phosphate for flagella formation in Escherichia coli and Salmonella typhimurium.

Authors:  T Yokota; J S Gots
Journal:  J Bacteriol       Date:  1970-08       Impact factor: 3.490

9.  Cyclic adenosine monophosphate in bacteria.

Authors:  I Pastan; R Perlman
Journal:  Science       Date:  1970-07-24       Impact factor: 47.728

10.  Adenosine 3':5'-cyclic monophosphate concentration in the bacterial host regulates the viral decision between lysogeny and lysis.

Authors:  J S Hong; G R Smith; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1971-09       Impact factor: 11.205

View more
  143 in total

1.  Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system.

Authors:  María Dolores Juárez-Rodríguez; Lourdes T Arteaga-Cortés; Rebin Kader; Roy Curtiss; Josephine E Clark-Curtiss
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 2.  Cyclic AMP in prokaryotes.

Authors:  J L Botsford; J G Harman
Journal:  Microbiol Rev       Date:  1992-03

Review 3.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

4.  Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans.

Authors:  A K Turner; T D Terry; D A Sack; P Londoño-Arcila; M J Darsley
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

5.  Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.

Authors:  J Y Wang; M F Pasetti; F R Noriega; R J Anderson; S S Wasserman; J E Galen; M B Sztein; M M Levine
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines.

Authors:  Tie Liu; Rolf König; Jian Sha; Stacy L Agar; Chien-Te K Tseng; Gary R Klimpel; Ashok K Chopra
Journal:  Microb Pathog       Date:  2007-10-06       Impact factor: 3.738

7.  Leucine-responsive regulatory protein (Lrp) acts as a virulence repressor in Salmonella enterica serovar Typhimurium.

Authors:  Chang-Ho Baek; Shifeng Wang; Kenneth L Roland; Roy Curtiss
Journal:  J Bacteriol       Date:  2008-12-12       Impact factor: 3.490

8.  Antibody response and protection against challenge in mice vaccinated intraperitoneally with a live aroA O4-O9 hybrid Salmonella dublin strain.

Authors:  A A Lindberg; T Segall; A Weintraub; B A Stocker
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Oral vaccination of calves with an aromatic-dependent Salmonella dublin (O9,12) hybrid expressing O4,12 protects against S. dublin (O9,12) but not against Salmonella typhimurium (O4,5,12).

Authors:  T Segall; A A Lindberg
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

10.  Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A of Streptococcus sobrinus: persistence and induction of humoral responses in rats.

Authors:  T K Redman; C C Harmon; S M Michalek
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.